Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Eden vs Center for Medical Weight Loss (CMWL)

Two GLP-1 desks, one scoreboard. We put Eden and Center for Medical Weight Loss (CMWL) head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 3 · Grade A−

Eden

Visit Eden Full brief →
vs
No. 153 · Grade C

Center for Medical Weight Loss (CMWL)

Visit Center for Medical Weight Loss (CMWL) Full brief →

The verdict

Eden takes this head-to-head.

Eden scores 91 to 68 on our six-factor Brief Score — A polished, high-disclosure program with strong nationwide coverage — you pay more, but you know exactly what you're paying for.

That doesn't make Center for Medical Weight Loss (CMWL) a bad call — it's best for readers who want budget-conscious patients wanting flat any-dose compounded glp-1 from an established program. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
89
66
Supply Reliability
92
73
Transparency
93
72
Access Breadth
90
50
Clinical Oversight
92
78
Track Record
89
70
EdenBrief Score 91 · 68Center for Medical Weight Loss (CMWL)

Price, coverage & the tracker

EdenCenter for Medical Weight Loss (CMWL)
Brief Score91/100 (A−)68/100 (C)
Semaglutide$239/moFrom $149/mo (all doses, compounded)
Tirzepatide$349/moFrom $239/mo (all doses, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

Eden: Premium line steady; high supply-chain disclosure keeps our confidence high.

Center for Medical Weight Loss (CMWL): New to the tracker on 1 August 2026. The published line reads From $149/mo (all doses, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.